IL201834A0 - Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor - Google Patents

Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor

Info

Publication number
IL201834A0
IL201834A0 IL201834A IL20183409A IL201834A0 IL 201834 A0 IL201834 A0 IL 201834A0 IL 201834 A IL201834 A IL 201834A IL 20183409 A IL20183409 A IL 20183409A IL 201834 A0 IL201834 A0 IL 201834A0
Authority
IL
Israel
Prior art keywords
reversible
intravenous
inhibitor
acting
direct
Prior art date
Application number
IL201834A
Other languages
English (en)
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of IL201834A0 publication Critical patent/IL201834A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL201834A 2007-05-02 2009-10-29 Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor IL201834A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91564907P 2007-05-02 2007-05-02
US94792107P 2007-07-03 2007-07-03
PCT/US2008/062518 WO2008137753A2 (en) 2007-05-02 2008-05-02 Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor

Publications (1)

Publication Number Publication Date
IL201834A0 true IL201834A0 (en) 2010-06-16

Family

ID=39587015

Family Applications (1)

Application Number Title Priority Date Filing Date
IL201834A IL201834A0 (en) 2007-05-02 2009-10-29 Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor

Country Status (17)

Country Link
US (2) US20090048216A1 (es)
EP (1) EP2079464A2 (es)
JP (1) JP2010526101A (es)
KR (1) KR20100029746A (es)
CN (1) CN101795682A (es)
AU (1) AU2008247483A1 (es)
BR (1) BRPI0811476A2 (es)
CA (1) CA2686203A1 (es)
CO (1) CO6241104A2 (es)
EA (1) EA200901473A1 (es)
EC (1) ECSP099778A (es)
GT (1) GT200900284A (es)
IL (1) IL201834A0 (es)
MA (1) MA31663B1 (es)
MX (1) MX2009011843A (es)
TN (1) TN2009000451A1 (es)
WO (1) WO2008137753A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8058284B2 (en) * 2005-11-03 2011-11-15 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
AU2008223831B2 (en) * 2007-03-06 2012-07-05 Novartis Ag Bicyclic organic compounds suitable for the treatment of inflammatory or allergic conditions
EA200901474A1 (ru) * 2007-05-02 2010-04-30 Портола Фармасьютиклз, Инк. Соли [4-(6-фтор-7-метиламино-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины в различных кристаллических формах и фармацевтические композиции на их основе
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
US9427448B2 (en) * 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
JP5851246B2 (ja) * 2008-12-30 2016-02-03 リグスホスピタルＲｉｇｓｈｏｓｐｉｔａｌｅｔ 臓器不全の発生リスクが上昇した重篤患者を識別する方法およびその治療のための化合物
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
BR112012011298B1 (pt) 2009-11-11 2021-12-14 Chiesi Farmaceutici S.P.A. Uso de cangrelor e/ou bivalirudina na preparação de medicamentos e combinação de medicamentos
ES2548845T3 (es) * 2009-12-23 2015-10-21 Ratiopharm Gmbh Forma de dosificación farmacéutica sólida de ticagrelor y ácido acetilsalicílico
WO2011088152A1 (en) 2010-01-12 2011-07-21 Portola Pharmaceuticals, Inc. Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
WO2011137459A1 (en) * 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
WO2012072743A1 (en) * 2010-12-01 2012-06-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and kits for determining platelet susceptibility to activation in a patient
CN103339126B (zh) * 2010-12-03 2016-06-29 博尔托拉制药公司 式(i)化合物的固态形式及其药物组合物、剂型和使用方法
US11179390B2 (en) 2017-03-15 2021-11-23 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a P2Y12 receptor antagonist
WO2018234565A1 (en) 2017-06-23 2018-12-27 Chiesi Farmaceutici S.P.A. METHOD FOR PREVENTING SHUNT THROMBOSIS FROM THE SYSTEMIC-PULMONARY ARTERY
CN107462648B (zh) * 2017-08-21 2019-09-27 盐城锦明药业有限公司 一种Cangrelor中间体腺苷-2-硫酮的高效液相色谱检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
US8058284B2 (en) 2005-11-03 2011-11-15 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto

Also Published As

Publication number Publication date
MX2009011843A (es) 2010-04-22
BRPI0811476A2 (pt) 2014-11-04
KR20100029746A (ko) 2010-03-17
WO2008137753A3 (en) 2009-02-12
GT200900284A (es) 2012-01-31
JP2010526101A (ja) 2010-07-29
MA31663B1 (fr) 2010-09-01
TN2009000451A1 (en) 2011-03-31
CA2686203A1 (en) 2008-11-13
EP2079464A2 (en) 2009-07-22
EA200901473A1 (ru) 2010-06-30
US20120009172A1 (en) 2012-01-12
CO6241104A2 (es) 2011-01-20
US20090048216A1 (en) 2009-02-19
WO2008137753A2 (en) 2008-11-13
ECSP099778A (es) 2010-01-29
AU2008247483A1 (en) 2008-11-13
CN101795682A (zh) 2010-08-04

Similar Documents

Publication Publication Date Title
BRPI0811476A2 (pt) Dosagem intravenosa e oral de um inibidor de p2y12 de ação direta e reversível
IL219583A0 (en) Oral formulations of a hedgehog pathway inhibitor, methods of producing the same and uses thereof
TWI561183B (en) Oral care implement
PL2185198T3 (pl) Inhibitory LOX i L0XL2 oraz ich zastosowania
LT2807926T (lt) Tetraciklino junginio druskos ir polimorfai
EP2047820A4 (en) ORTHODONTIC FASTENING BRIDGE
ZA200808361B (en) DPP IV inhibitor formulations
GB0625659D0 (en) Therapeutic compounds and their use
PL2957278T3 (pl) STABILNA KOMPOZYCJA ZAWIERAJĄCA PTHrP ORAZ JEJ ZASTOSOWANIA
GB0703438D0 (en) Preventing spread of infection
PL2402317T3 (pl) Inhibitor DGAT
PT2173345E (pt) Formulação oral de metadoxina
IL213694A0 (en) Melanin production inhibitor compounds and compositions comprising the same
AP2008004686A0 (en) New form of administration of racecadotril
GB0710439D0 (en) Oral dosage form
IL202765A0 (en) Pharmaceutical combination of nsaid and prostaglandin compound
PL2271348T3 (pl) Doustny preparat związków tetracyklinowych w postaci tabletki
EP2081606A4 (en) HYGIENE ARTICLE CONTAINING AN ANTI-MICROBIAL COMPOSITION
ZA201103752B (en) Cycloundecadepsipeptide compounds and use of said compounds as a medicament
EP2195316A4 (en) ACTIVATORS AND THERAPEUTIC APPLICATIONS THEREOF
IL228484A0 (en) 2-mmp and/or 9-mmp inhibitors
PL2046268T3 (pl) Kompozycja do pielęgnacji jamy ustnej
EP2039362A4 (en) INHIBITOR OF THE DISSOLUTION OF DENTAL ENAMEL
HK1131567A (en) Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor
GB2453072B (en) Oral care compositions